Studies have suggested that screening for a given type of cancer could be used to promote participation in other types. Specifically, breast cancer (BC) screening tends to have a higher part...
Click to read this study in The Lancet Oncology....
Click to read this study in The Lancet Oncology....
Click to read this study in JAMA Network Open. ...
A single assessment of the circulating tumor cells (CTC) count before treatment can guide the treatment decision between chemotherapy and single-agent endocrine therapy in ER-positive/HER2-n...
In vitro studies using DNA barcoded cell lines demonstrated that resistance to CDK4/6 inhibitors is likely due to the expansion of pre-existing resistant clones, suggesting that targeting re...
Among patients with HR-positive/HER2-negative metastatic breast cancer, combining palbociclib with fulvestrant beyond progression on prior CDK4/6 inhibition did not significantly improve pro...
Duration of first-line CDK4/6 inhibitor therapy in patients with ER-positive/HER2-negative metastatic breast cancer is associated with duration of progression-free survival (PFS) of subseque...
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastati...
In women carrying a germline pathogenic variant for breast cancer, like BRCA1, BRCA2, or CHEK2, the risk for contralateral breast cancer is also increased, data from a sub-analysis of the CA...
Paclitaxel/cemiplimab/fianlimab is a highly effective combination for neoadjuvant therapy in both triple-negative breast cancer (TNBC) and HR-positive/HER2-negative breast cancer. In additio...
Patients with breast cancer who pause their endocrine therapy to try to get pregnant experienced short-term rates of breast cancer recurrence similar to women who do not pause therapy for pr...
In addition to predicting the benefit of adjuvant chemotherapy in patients with early breast cancer, the 70-gene MammaPrint also predicts who benefits from extended endocrine therapy, result...
Physical and psychosocial symptoms, such as pain, are common after breast cancer treatment is completed. “In some patients, pain becomes chronic, persisting for months or even years,” ex...
Chemo-endocrine therapy has a greater negative effect on cancer-related cognitive impairment compared with endocrine therapy alone in both pre- and postmenopausal women, results from the RxR...
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated in the neoadjuvant setting with trastuzumab deruxtecan had an overall response rate of 68% in the absence o...
With additional follow-up, the benefit of adjuvant abemaciclib for patients with HR-positive/HER2-negative, node-positive, high-risk early breast cancer continues to deepen in magnitude afte...
A first prospective, head-to-head study showed superior progression-free survival of ribociclib plus endocrine therapy over combination chemotherapy in patients with aggressive HR-positive/H...
Residual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy have a higher score of a biomarker of dista...
Everyone knows that a certain pink ribbon is a symbol for breast cancer awareness. From NFL players who display them on their uniforms to businesses who exhibit them on their check-out count...
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
